BC Platforms partners with Sentieon


The collaboration will aim to provide precision medicine solutions on a population scale

BC Platforms partners with Sentieon

BC Platforms, a specialist in genomic data management and analysis solutions, announced it has partnered with Sentieon to integrate Sentieon’s award winning NGS data processing software into BC Platform’s highly scalable integrated genomics and clinical data solutions.

This combination of technologies will provide an integrated system enabling highly accurate sample by sample clinical work to extensive population scale biobank analysis.

Jun Ye, CEO at Sentieon, commented: “Sentieon is thrilled to partner with one of the most experienced and respected genomic software companies in the world. Enabling Precision Medicine is a complex problem and by working together and combining each company’s core expertise we can better serve our customers.”

“We are very happy to add our award winning secondary analysis tools into BC Platforms downstream analytics and data management solution to create a complete genomic medicine system.”

BC Platforms has developed a technology capable of downstream analysis of thousands of genomes per day, using either genotype arrays or next generation sequencing.

The introduction of Sentieon's scalable, clinical quality and hardware agnostic software tools for NGS data processing further extends BC Platform’s world class precision medicine solution, both in cloud and on-premise.

Tero Silvola, CEO at BC Platforms, said: “We are delighted to partner with Sentieon to incorporate their NGS processing software into our genomics and clinical data analysis offering for our customers. We are committed to working with our partners to advance the use of genomics and clinical data to enable precision medicine solutions on a population scale.”

Sign up for your free email newsletter

“This partnership will provide our customers access to an end-to-end solution and the confidence to scale to any size in their quest to deliver on the promise of precision medicine for their patients.”